Members of the Ras/RAF/MEK/ERK pathway, in particular KRAS and BRAF, are frequently deregulated in several cancers including melanoma, colorectal (CRC), non-small cell lung cancer (NSCLC) and pancreatic (Sebolt-Leopold and Herrera, 2004). Here, BRAF is linked to non-small cell lung carcinoma.